Vanguard Group’s Kindred Biosciences, Inc. KIN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,890,913
| Closed | -$17.3M | – | 4573 |
|
|
2021
Q2 | $17.3M | Sell |
1,890,913
-111,957
| -6% | -$651K | ﹤0.01% | 2921 |
|
|
2021
Q1 | $9.95M | Buy |
2,002,870
+19,845
| +1% | +$95.8K | ﹤0.01% | 3148 |
|
|
2020
Q4 | $8.55M | Buy |
1,983,025
+18,577
| +0.9% | +$75.6K | ﹤0.01% | 3072 |
|
|
2020
Q3 | $8.43M | Sell |
1,964,448
-13,779
| -0.7% | -$57.6K | ﹤0.01% | 2871 |
|
|
2020
Q2 | $8.88M | Buy |
1,978,227
+55,464
| +3% | +$248K | ﹤0.01% | 2837 |
|
|
2020
Q1 | $7.69M | Buy |
1,922,763
+17,715
| +0.9% | +$150K | ﹤0.01% | 2740 |
|
|
2019
Q4 | $16.2M | Buy |
1,905,048
+20,994
| +1% | +$164K | ﹤0.01% | 2631 |
|
|
2019
Q3 | $12.9M | Buy |
1,884,054
+175,120
| +10% | +$1.28M | ﹤0.01% | 2697 |
|
|
2019
Q2 | $14.2M | Buy |
1,708,934
+30,940
| +2% | +$267K | ﹤0.01% | 2674 |
|
|
2019
Q1 | $15.4M | Buy |
1,677,994
+254,538
| +18% | +$2.58M | ﹤0.01% | 2622 |
|
|
2018
Q4 | $15.6M | Buy |
1,423,456
+13,442
| +1% | +$169K | ﹤0.01% | 2556 |
|
|
2018
Q3 | $19.7M | Buy |
1,410,014
+80,023
| +6% | +$1.08M | ﹤0.01% | 2585 |
|
|
2018
Q2 | $14.2M | Buy |
1,329,991
+210,077
| +19% | +$2.05M | ﹤0.01% | 2729 |
|
|
2018
Q1 | $9.69M | Buy |
1,119,914
+103,369
| +10% | +$907K | ﹤0.01% | 2839 |
|
|
2017
Q4 | $9.61M | Buy |
1,016,545
+167,145
| +20% | +$1.31M | ﹤0.01% | 2839 |
|
|
2017
Q3 | $6.67M | Buy |
849,400
+104,078
| +14% | +$781K | ﹤0.01% | 3003 |
|
|
2017
Q2 | $6.41M | Buy |
745,322
+272,612
| +58% | +$1.96M | ﹤0.01% | 2993 |
|
|
2017
Q1 | $3.33M | Buy |
472,710
+44,062
| +10% | +$276K | ﹤0.01% | 3211 |
|
|
2016
Q4 | $1.82M | Sell |
428,648
-5,689
| -1% | -$27.5K | ﹤0.01% | 3389 |
|
|
2016
Q3 | $2.16M | Buy |
434,337
+1,400
| +0.3% | +$5.92K | ﹤0.01% | 3358 |
|
|
2016
Q2 | $1.53M | Buy |
432,937
+7,098
| +2% | +$26.1K | ﹤0.01% | 3468 |
|
|
2016
Q1 | $1.47M | Buy |
425,839
+7,830
| +2% | +$27.7K | ﹤0.01% | 3482 |
|
|
2015
Q4 | $1.42M | Buy |
418,009
+38,641
| +10% | +$179K | ﹤0.01% | 3516 |
|
|
2015
Q3 | $1.97M | Buy |
379,368
+9,028
| +2% | +$55.7K | ﹤0.01% | 3382 |
|
|
2015
Q2 | $2.53M | Sell |
370,340
-2,461
| -0.7% | -$17.5K | ﹤0.01% | 3322 |
|
|
2015
Q1 | $2.66M | Buy |
372,801
+37,881
| +11% | +$261K | ﹤0.01% | 3287 |
|
|
2014
Q4 | $2.5M | Buy |
334,920
+30,548
| +10% | +$259K | ﹤0.01% | 3200 |
|
|
2014
Q3 | $2.82M | Buy |
304,372
+72,531
| +31% | +$980K | ﹤0.01% | 3122 |
|
|
2014
Q2 | $4.32M | Buy |
231,841
+80,689
| +53% | +$1.37M | ﹤0.01% | 2911 |
|
|
2014
Q1 | $2.8M | Buy |
+151,152
| New | +$2.88M | ﹤0.01% | 3070 |
|
Other funds holding KIN
Vanguard Group's KIN Position: Q3 2021 in Review
Vanguard Group sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 1,890,913 shares — an estimated $17.3M sold.
Vanguard Group first reported a position in KIN in Q1 2014 and held it in 30 quarters. The position peaked at $19.7M in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.
- Vanguard Group reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Vanguard Group sold 1,890,913 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $17.3M.
- Vanguard Group first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 30 quarters.
- Vanguard Group's Kindred Biosciences, Inc. position peaked at $19.7M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.
Based on Vanguard Group's 13F filing for Q3 2021, filed 12 Nov 2021.